---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-001964"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T00:53:18.274121+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Passage Bio reports PBGM01 interim data: MRI stabilization, biomarker decreases in GM1 gangliosidosis trial

## Summary
- All six treated patients showed stabilization of MRI severity scores over 6-12 months follow-up.
- High-dose PBGM01 resulted in 3.6-5.2x increase in CSF β-gal activity, sustained up to 12 months.
- No treatment-related serious adverse events, DRG toxicity, or complications from ICM delivery.
- Urine Dp5 levels decreased in high-dose patients, indicating peripheral β-gal activity.
- Milder developmental delay at baseline associated with improved treatment response.

## SEC filing metadata
- accession: 0001558370-23-001964
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837023001964/0001558370-23-001964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837023001964/pasg-20230224x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-001964
- JSON: https://secwatch.observer/filing/0001558370-23-001964.json
- Plain text: https://secwatch.observer/filing/0001558370-23-001964.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.